Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00677755
Other study ID # Taizhou2004-08
Secondary ID
Status Completed
Phase N/A
First received May 7, 2008
Last updated May 15, 2008
Start date October 2004
Est. completion date November 2007

Study information

Verified date May 2008
Source Taizhou Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy, safety and acceptability of pre-treatment with mifepristone and misoprostol compared to misoprostol alone in the medical termination of pregnancy by mifepristone EC failure.


Description:

Women usually request an abortion when they have experienced an emergency contraception (EC) failure; this population represents 13% of all early pregnancy terminations in China. Many women would prefer to choose a medical abortion in order to avoid anesthesia, over a surgical operation. However, medical termination of a pregnancy after mifepristone EC failure has not been studied although it has already been extensively practiced by empirical means in China. There is no clarification in literature as to whether mifepristone is still effective in medical abortion with its previous failure experience in EC. This randomized study was aimed to compare the efficacy, safety and acceptability of pre-treatment with mifepristone and misoprostol compared to misoprostol alone in the medical termination of pregnancy by mifepristone EC failure.


Recruitment information / eligibility

Status Completed
Enrollment 394
Est. completion date November 2007
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Female
Age group 16 Years to 40 Years
Eligibility Inclusion Criteria:

- Participants included in the study were women aged 16 years or older

- with good general health,

- experiencing a mifepristone emergency contraception failure,

- presenting an intrauterine singleton pregnancy confirmed by pelvic ultrasound scan, with a crown-rump length compatible within 56 days of gestation at the enrolled day, and

- seeking a medical abortion for unwanted pregnancy.

- Women who had a threatened abortion or a failure pregnancy were also included.

- Participants were required to sign an informed consent form before enrolment, willing to comply with the schedule of follow-up visits and willing to undergo surgical aspiration if indicated.

Exclusion Criteria:

- The exclusion criteria included suspected or proven ectopic pregnancy,

- allergy or contraindications for mifepristone (chronic systemic corticosteroid therapy, adrenal insufficiency) or misoprostol (hypertension, mitral stenosis, severe asthma, glaucoma, sickle cell anemia and hypotension),

- history or evidence of thromboembolism, cardiovascular disease or liver disease, hemoglobin = 90 g/l, heavy smoking (more than 10 per day),

- presence of an intrauterine device, and breastfeeding.

- Other exclusion criteria included participants who had EC failure because incorrect use, for example, having further unprotected intercourse after EC.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
mifepristone combined misoprostol
women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
misoprostol alone protocol
patients were only administered 0.8 mg of misoprostol orally on day 3.

Locations

Country Name City State
China Taizhou Hospital of zhejiang Province Taizhou City Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Taizhou Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary complete abortion rate study day 17 (14 days after misoprostol) No
Secondary side effects, timing of expulsion and duration of bleeding timing of expulsion at day 17, others at 45day after abortion Yes
See also
  Status Clinical Trial Phase
Completed NCT01541293 - Intrauterine Lidocaine for Laminaria Phase 1
Completed NCT00177333 - Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Phase 4
Completed NCT00370487 - Comparison of the Safety of First Trimester Abortions Performed by Physicians and Non-Physicians in South Africa and Viet Nam. N/A
Completed NCT00188071 - Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen N/A
Completed NCT02277249 - Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion N/A
Completed NCT00386867 - A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP N/A
Completed NCT02279914 - Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial N/A
Completed NCT01615731 - Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks N/A
Completed NCT01597726 - Cervical Priming Before Dilation & Evacuation N/A
Completed NCT02318212 - Dilapan-S / Dilasoft E-Registry in Induced Abortion N/A
Terminated NCT00855842 - Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion N/A
Completed NCT00330993 - Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation Phase 2
Completed NCT00382538 - Mifepristone and Mid-Trimester Termination of Pregnancy N/A
Completed NCT03080493 - Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial Phase 4
Completed NCT02485444 - Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion Phase 4
Completed NCT00969982 - Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP)) N/A
Recruiting NCT02480543 - Different Routes of Misoprostol Prior to First Trimester Surgical Abortion Phase 4
Completed NCT00870272 - Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP) N/A
Completed NCT02048098 - Misoprostol for Second Trimester Termination of Pregnancy Phase 3
Completed NCT01751087 - Cervical Preparation Before Dilation and Evacuation N/A